Discover
KURA
Kura Oncology, Inc.
10.89
1 x 10.75
1 x 11.00
bid
ask
+
0.21
1.97%
1 @ 04:00 PM
10.93 +0.04 (0.37%)
| Ytd | 4.81% | |
| 1y | 63.27% |
10.48
day range
10.92
5.45
52 week range
12.49
| Open | 10.65 | Prev Close | 10.68 | Low | 10.48 | High | 10.92 | Mkt Cap | 966.75M |
| Vol | 1.22M | Avg Vol | 1.73M | EPS | -3.35 | P/E | -3.25 | Forward P/E | -4.41 |
| Beta | 0.35 | Short Ratio | 7.94 | Inst. Own | 96.84% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 10.14 | 200-d Avg | 9.64 | 1yr Est | 31.17 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-08-06 | 2026-06 | -0.89 | N/A | N/A | N/A |
| 2026-05-12 | 2026-03 | -0.88 | -0.83 | 0.05 | 5.68% |
| 2026-03-05 | 2025-12 | -0.72 | -0.92 | -0.2 | -27.78% |
| 2025-11-04 | 2025-09 | -0.57 | -0.85 | -0.28 | -49.12% |
| 2025-08-07 | 2025-06 | 0.15 | -0.75 | -0.9 | -600.00% |
| 2025-05-01 | 2025-03 | -0.51 | -0.66 | -0.15 | -29.41% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-06-15 | Citizens | Upgrade | Market Outperform | Market Outperform |
| 2026-04-14 | Lake Street | Upgrade | Buy | |
| 2026-03-24 | Mizuho | Upgrade | Outperform | Outperform |
| 2026-03-13 | UBS | Upgrade | Buy | Buy |
| 2026-03-06 | Wedbush | Upgrade | Outperform | Outperform |
| 2026-01-13 | Leerink Partners | Upgrade | Outperform | Outperform |
Profile
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2026-05-17 | BAIR TERESA BROPHY | Officer | 226.93K | Sale |
| 2026-01-26 | BURROWS FRANCIS J. PH.D. | Officer | 32.42K | Sale |
| 2026-01-26 | DOYLE THOMAS JAMES | Officer | 145.67K | Sale |
| 2026-05-18 | FORD KATHLEEN | Chief Operating Officer | 153.56K | Sale |
| 2025-12-08 | HASNAIN FAHEEM | Director | 23.98K | Sale |
| 2026-06-17 | LEONI MOLLIE M.D. | Officer | 182.35K | Sale |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | BlackRock Inc | 9.64M | 0.00 | 10.86% |
| 2026-03-30 | Suvretta Capital Management, LLC | 8.58M | 0.00 | 9.66% |
| 2026-03-30 | Bvf Inc | 8.45M | 0.00 | 9.51% |
| 2025-12-30 | Vanguard Group Inc | 5.51M | 0.00 | 6.20% |
| 2026-03-30 | State Street Corp | 4.51M | 0.00 | 5.08% |
| 2026-03-30 | Vanguard Capital Management, LLC | 3.79M | 0.00 | 4.26% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-05-30 | State Street® SPDR® S&P® Biotech ETF | 2.79M | 0.00 | 3.15% |
| 2026-04-29 | Vanguard Total Stock Mkt Idx Inv | 2.73M | 0.00 | 3.07% |
| 2026-05-28 | iShares Russell 2000 ETF | 1.91M | 0.00 | 2.15% |
| 2026-03-30 | HBM Healthcare Investments AG Ord | 1.79M | 0.00 | 2.01% |
| 2026-04-29 | Vanguard Institutional Extnd Mkt Idx Tr | 981.99K | 0.00 | 1.11% |
| 2026-03-30 | Fidelity Small Cap Index | 789.60K | 0.00 | 0.89% |